<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023253</url>
  </required_header>
  <id_info>
    <org_study_id>108003-F</org_study_id>
    <nct_id>NCT04023253</nct_id>
  </id_info>
  <brief_title>Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin</brief_title>
  <official_title>Comparisons of the Impact of Beta-3 Agonist Versus Antimuscarinics on Psychological Distress, Sexual Function, Bladder Wall Thickness and Blood Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the impact of mirabegron versus solifenacin on psychological distress, sexual
      function, bladder wall thickness and bladder blood flow.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the impact of mirabegron versus solifenacin on psychological distress, sexual
      function, bladder wall thickness and blood flow.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global response assessment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Between-group difference in the score of Global response assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total score of Brief Symptoms Rating Scales</measure>
    <time_frame>12 weeks</time_frame>
    <description>Between-group difference in the changes of total score of Brief Symptoms Rating Scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female sexual function index</measure>
    <time_frame>12 weeks</time_frame>
    <description>Between-group difference in the changes of total score of female sexual function index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder wall thickness</measure>
    <time_frame>12 weeks</time_frame>
    <description>Between-group difference in the changes of bladder wall thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood flow index of the bladder</measure>
    <time_frame>12 weeks</time_frame>
    <description>Between-group difference in the changes of blood flow index of the bladder</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Overactive Bladder Syndrome</condition>
  <arm_group>
    <arm_group_label>mirabegron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive mirabegron 2 mg treatment per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>solifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive solifenacin 5 mg treatment per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Mirabegron 25 mg</description>
    <arm_group_label>mirabegron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin</intervention_name>
    <description>Solifenacin 5 mg</description>
    <arm_group_label>solifenacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overactive bladder syndrome

        Exclusion Criteria:

          -  Allergy to mirabegron or solifenacin.

          -  Patients with severe hypertension who are difficult to control, known urethral
             diverticulum, known bladder malignant tumors, urinary retention patients, gastric
             retention patients, uncontrolled angular glaucoma patients, dialysis patients, severe
             renal dysfunction , moderate liver dysfunction, use strong inhibitors of CYP3A4 such
             as ketoconazole.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng-Mou Hsiao, MD</last_name>
    <phone>+886289667000</phone>
    <phone_ext>1818</phone_ext>
    <email>smhsiao2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital</name>
      <address>
        <city>Banqiao</city>
        <state>New Taipei</state>
        <zip>22050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Mou Hsiao, M.D.</last_name>
      <phone>+886-2-89667000</phone>
      <phone_ext>1818</phone_ext>
      <email>smhsiao2@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>October 19, 2019</last_update_submitted>
  <last_update_submitted_qc>October 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Sheng-Mou Hsiao</investigator_full_name>
    <investigator_title>Chief and Associate Professor, Department of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

